Benzinga | Nov 2, 2021 06:30PM EDT

UPDATE: Halozyme Therapeutics Q3 Adj. EPS $0.55 Beats $0.42 Estimate, Sales $115.83M Beat $101.94M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.42 by 30.95 percent. This is a 77.42 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $115.83 million which beat the analyst consensus estimate of $101.94 million by 13.63 percent. This is a 77.34 percent increase over sales of $65.32 million the same period last year.